Condition: Angiosarcoma of Skin · Sponsor: Athenex, Inc.
This is a non-blinded, multi-center, open-label, phase 2 study to evaluate the activity, safety, and tolerability of Oraxol in subjects with cutaneous angiosarcoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| Texas Oncology | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| University of Washington/Fred Hutchinson Cancer Center | Seattle, Washington, United States | — |
| Prince of Wales Hospital, Shatin | Hong Kong, Hong Kong | — |
| National Taiwan University Hospital | Taipei, Taiwan | — |
| Taipei Veterans General Hosptial | Taipei, Taiwan | — |
| University College London Hospitals NHS Foundation Trust | London, United Kingdom | — |
| The Royal Marsden NHS Foundation Trust | London, United Kingdom | — |
| The Christie NHS Foundation Trust, Manchester | Manchester, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03544567